MAP2K7 and hepatocellular carcinoma: It has been shown that miR-216a-3p downregulates MAPK14 expression and inhibits the activation of the MEK/ERK and ATF2 signaling pathways, enhancing HCC cells’ sensitivity to sorafenib [71].